Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfameter (also known as sulfamethoxydiazine or sulfametoxydiazine) is a long-acting sulfonamide antibacterial agent. It is used primarily in the treatment of urinary tract infections and as a leprostatic agent for leprosy. Sulfameter acts as a bacteriostatic antibiotic by inhibiting bacterial dihydropteroate synthase, an enzyme involved in the synthesis of dihydrofolic acid from para-aminobenzoic acid (PABA), thereby blocking folic acid synthesis essential for bacterial growth and replication. This mechanism leads to inhibition of DNA and RNA synthesis in susceptible Gram-positive and Gram-negative bacteria[1][2][3][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfameter.